share_log

HC Wainwright & Co. Maintains Buy on Medicenna Therapeutics, Lowers Price Target to $4

Benzinga Real-time News ·  Aug 16, 2022 18:28

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Medicenna Therapeutics (NASDAQ:MDNA) with a Buy and lowers the price target from $5 to $4.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment